High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study

被引:0
作者
Markus Bickel
Christian Hoffmann
Eva Wolf
Axel Baumgarten
Christoph Wyen
Christoph D. Spinner
Hans Jäger
Nils Postel
Stefan Esser
Markus Mueller
Albrecht Stoehr
Stefan Preis
Stephan Klauke
Knud Schewe
机构
[1] Infektiologikum Frankfurt,Department of Internal Medicine I
[2] ICH Study Center,School of Medicine
[3] University of Schleswig-Holstein Campus Kiel,Department of Dermatology and Venerology
[4] MUC Research,undefined
[5] Center for Infectiology Berlin Prenzlauer Berg GmbH (Zibp),undefined
[6] dagnae e.V.,undefined
[7] Praxis Ebertplatz,undefined
[8] University Hospital Cologne,undefined
[9] Technical University of Munich,undefined
[10] MVZ Karlsplatz,undefined
[11] HIV Research and Clinical Care Centre,undefined
[12] prinzmed,undefined
[13] Practice for Infectious Diseases,undefined
[14] University Hospital,undefined
[15] University HIV/STD Center Essen,undefined
[16] ifi Studien und Projekte GmbH an der Asklepios Klinik St. Georg,undefined
[17] Clinovate NET,undefined
来源
Infection | 2020年 / 48卷
关键词
HIV; Antiretroviral therapy; First-line treatment; Effectiveness; Treatment modification;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:453 / 461
页数:8
相关论文
共 86 条
[1]  
Carr A(2019)Success and failure of initial antiretroviral therapy in adults: an updated systematic review AIDS 33 443-453
[2]  
Richardson R(2016)High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda? Infection 44 347-352
[3]  
Liu Z(2019)Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016 Infection 47 247-255
[4]  
Schäfer G(2018)Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure AIDS 32 347-355
[5]  
Kreuels B(2017)Increased persistence of initial treatment for hiv infection with modern antiretroviral therapy J Acquir Immune Defic Syndr 76 111-115
[6]  
Schmiedel S(2018)Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort HIV Clinical Trials 19 52-60
[7]  
Hertling S(2017)HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies HIV Clin Trials 18 196-204
[8]  
Hüfner A(2016)HIV-1 drug resistance mutations emerging on darunavir therapy in PI naive and -experienced patients in the UK J Antimicrob Chemother 71 3487-3494
[9]  
Degen O(2018)Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe HIV Med 19 324-338
[10]  
van Lunzen J(2016)Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate Infection 44 641-649